Aitia is a leading AI-enabled biotech company focused on leveraging multi-omic patient data, high-performance computing, and causal AI to pioneer solutions in drug discovery and development.

Colin Hill

Iya Khalil

Aitia

Smile AI focuses on increasing online sales through its platform tailored for pharmaceutical e-commerce, self-described as a leader in the industry.

Smile AI

Novus Software specializes in developing software products tailored for the pharmaceutical industry, focusing on cloud technology, automation, and artificial intelligence (AI) to enhance operations and ensure compliance.

Novus Software

Aitia is the leader in the development and application of Causal AI and Digital Twins to discover the next generation of breakthrough drugs in neurodegenerative disorders, oncology, and immunology.  By leveraging the convergence of multi-omic patient data, high-performance computing, and causal learning and AI, Aitia is revealing the hidden biological mechanisms of disease to create Digital Twins. Gemini Digital Twins are being used today to discover novel therapies and accelerate R&D in Alzheimer’s Disease, Parkinson’s Disease, Huntington’s Disease, multiple myeloma, prostate cancer, and pancreatic cancer, with several more in development. Aitia’s partners include six of the top ten pharmaceutical companies, leading academic research and medical centers, medical societies, leading multi-omic data companies, and patient advocacy groups globally.

In the aftermath of the JP Morgan conference, articles continue to surface about the dominated role of AI and the spotlight it took this year, marking a notable shift in focus for biopharma.

🆕 Read what leaders and experts had to say about the impact of AI in biopharma in this recent STAT article: https://lnkd.in/eKBkQ_CM

#JPM24 #Aitia #ATeam #GeminiDigitalTwins #Gemini #drugdiscovery #CausalAI #GenerativeAI
Casey Ross

As JP Morgan conference fades into the rearview, the resonance of AI-Based Drug Discovery disrupting R&D grows louder. Throwback to our latest collaboration with Servier on Parkinson's Disease. 

Read the details in this press release if you haven't already: https://lnkd.in/eZziUqYK

#JPM24 #Aitia #ATeam #GeminiDigitalTwins #Gemini #drugdiscovery #ParkinsonsDisease #movedbyyou
Ross Jeggo, Jean-Michel Gries

👋 We are pleased to announce our new collaboration with Aitia focused on Parkinson’s disease.

This collaboration illustrates our #Servier2030 ambition to be a focused and innovative player in neuroscience. 

According to Ross Jeggo, Global Head of Neuroscience and Immuno-inflammation Therapeutic Area in the Research and Development department at Servier, 🗣 “This new collaboration with Aitia highlights Servier’s ambition to potentially provide innovative solutions to patients with high unmet medical needs.”

Congratulations 👏 to the teams who contribute to the success of this collaboration.

#DrugDiscovery #innovation #neuroscience #ParkinsonsDisease #GeminiDigitalTwins #Gemini #MovedByYou

We are delighted to announce the extension of our collaboration with Servier into the realm of Parkinson's Disease. This new venture complements our ongoing partnerships focused on pancreatic cancer and multiple myeloma. 

Further details in the press release: https://lnkd.in/eZziUqYK

If you are interested in exploring our research and collaboration initiatives in neuroscience, make sure to connect with our partnering team at J.P. Morgan  Conference this week. 

#JPM24 #Aitia #ATeam #GeminiDigitalTwins #Gemini #drugdiscovery #ParkinsonsDisease #movedbyyou #Servier

We’re excited to come together with the healthcare industry next week in San Francisco at #JPM24.

Make sure to reach out to our partnering team to learn more about our latest work and how we can join forces to discover novel targets and collaborate in drug simulations by leveraging the power of Gemini Digital Twins.

#JPM24 #Aitia #ATeam #GeminiDigitalTwins #Gemini #drugdiscovery

As the holiday cheer winds down, we are gearing up for the much-anticipated J.P. Morgan Healthcare Conference just days away!

If you're attending the Biotech Showcase or any of the other biotech/life science conferences and investment summits next week, make sure to connect with  Aitia Team! We're San Francisco-bound, all set to launch into an amazing 2024.

https://lnkd.in/eN-g4Qju

#JPM24 #Aitia #ATeam #GeminiDigitalTwins #Gemini #drugdiscovery
Colin Hill, Jean-Michel Gries

🎄Wishing you a happy holiday season and great success in the year to come! Season's greetings from the very merry #ATeam at Aitia ❄️

We are excited to announce the official launch of our new website! 

As a leading AI-enabled biotech company, our mission is to revolutionize drug discovery, challenging the traditional methods and pushing the boundaries of innovation.
 
🌐 Visit Aitiabio.com to learn more about our vision, approach, and people!

#Aitia #ATeam #GeminiDigitalTwins #Gemini #drugdiscovery

As we prepare to wrap up another exciting year for Aitia, we're eagerly looking forward to a bustling 2024. For now, we're gearing up for the J.P. Morgan conference, where our CEO Colin Hill and our President Jean-Michel Gries will be in attendance. Be sure to connect with them and request a meeting through the BIO partnering platform.

➡️ https://lnkd.in/dWvgeYi8

#JPM24 #Aitia #ATeam #DrugDiscovery #Gemini #GeminiDigitalTwins

What if an AI-based technology existed that could help treat pancreatic cancer?

📢 Spotlight on our collaboration with Servier to discover and simulate drugs in Pancreatic Cancer and gain deeper insights into the underlying mechanisms driving this complex disease to accelerate the discovery of new therapies for people living with pancreatic cancer.

Thank you Servier for this spotlight, we cherish our partnership and  we’re proud to be leading the charge against one of the cancers with the poorest prognosis!

➡️ Read what Servier had to say about his “Partner of Choice” in this article: https://lnkd.in/gWutbQFX

#PartnerOfChoice #Servier #Aitia #ATeam #Gemini #GeminiDigitalTwins #drugdiscovery 
Colin Hill, Fabien Schmidlin

Metric
Company Name	Aitia	Smile AI	Novus Software
Symbol
MSH ID	COM:AITIABIO	DE:SMILEAI	IN:NOVUSSOFTWARE
Market	PRIVATE	PRIVATE	PRIVATE
Sector	Healthcare	Technology	Technology
Industry	Biotechnology	Pharmaceutical E-Commerce	Pharmaceutical Software
Country	US	DE	IN
Stage		Seed
Employee Count	92
Website	aitiabio.com	smileai.de	novussoftware.in
LinkedIn	aitiabio	smileai	novussoftware
Founders

Metric
Market Cap
Enterprise Value
Monthly Web Traffic
Web Traffic Growth
Valuation
Raised Capital		113.32K

Metric
Revenue
Revenue (LTM)
Revenue (NTM)
Gross Profit
EBITDA
Operating Income
Net Income
EPS
Diluted EPS
Revenue 2022
Revenue 2023
Revenue 2024
Revenue 2025
Revenue 2026

Metric
Revenue Growth (LTM)
Revenue Growth (NTM)
Gross Profit Growth (LTM)
EBITDA Growth (LTM)
Net Income Growth (LTM)
14-Day Growth Score
28-Day Growth Score
90-Day Growth Score
365-Day Growth Score

Metric
Gross Profit Margin
Operating Profit Margin
EBITDA Margin
Net Profit Margin
Return on Equity
Return on Assets
Return on Capital Employed

COM:AITIABIO

Aitia

Company Overview

Market Metrics

Financial Performance

Growth Metrics

Profitability Ratios

Valuation Multiples

Operational Metrics

Cash Flow Metrics

Balance Sheet Metrics

Efficiency Metrics

Metric
P/E Ratio
P/B Ratio
Revenue Multiple (LTM)
Revenue Multiple (NTM)
EBITDA Multiple (LTM)
EBITDA Multiple (NTM)
Price to Sales Ratio
EV Multiple

Metric
Days Sales Outstanding
Days Payables Outstanding
Days Inventory Outstanding
Operating Cycle
Cash Conversion Cycle
Asset Turnover

Metric
Operating Cash Flow
Free Cash Flow
Cash Flow to Debt
Operating Cash Flow/Sales
Free Cash Flow Yield

Metric
Cash & Equivalents
Accounts Receivable
Inventory
Goodwill
Debt to Capitalization
Debt to Assets
Current Ratio
Quick Ratio

Metric
Rule of 40 (LTM)
Rule of 40 (NTM)
Stock Comp to Revenue
R&D to Revenue
SG&A to Revenue